Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview

Detalhes bibliográficos
Autor(a) principal: Calmeiro, João
Data de Publicação: 2021
Outros Autores: Carrascal, Mylène A., Tavares, Adriana Ramos, Ferreira, Daniel Alexandre, Gomes, Célia, Cruz, Maria Teresa, Falcão, Amílcar, Neves, Bruno Miguel
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10773/37674
Resumo: In the last decade, immunotherapy led to a paradigm shift in the treatment of numerous malignancies. Alongside with monoclonal antibodies blocking programmed cell death receptor-1 (PD-1)/PD-L1 and cytotoxic T- lymphocyte antigen 4 (CTLA-4) immune checkpoints, cell-based approaches such as CAR-T cells and dendritic cell (DC) vaccines have strongly contributed to pushing forward this thrilling field. While initial strategies were mainly focused on monotherapeutic regimens, it is now consensual that the combination of immunotherapies tackling multiple cancer hallmarks can result in superior clinical outcomes. Here, we review in depth the pharmacological combination of DC-based vaccines that boost tumour elimination by eliciting and expanding effector immune cells, with the PD-1 inhibitor Nivolumab that allows blocking key tumour immune escape mechanisms. This combination represents an important step in cancer therapy, with a significant enhancement in patient survival in several types of tumours, paving an important way in establishing combinatorial immunotherapeutic strategies as first-line treatments.
id RCAP_bbbc6eb4488e86f7f2244734f29e54c1
oai_identifier_str oai:ria.ua.pt:10773/37674
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overviewAntitumour immunotherapyImmune checkpoint inhibitorsNivolumabDendritic cell vaccinesCombinatory therapiesIn the last decade, immunotherapy led to a paradigm shift in the treatment of numerous malignancies. Alongside with monoclonal antibodies blocking programmed cell death receptor-1 (PD-1)/PD-L1 and cytotoxic T- lymphocyte antigen 4 (CTLA-4) immune checkpoints, cell-based approaches such as CAR-T cells and dendritic cell (DC) vaccines have strongly contributed to pushing forward this thrilling field. While initial strategies were mainly focused on monotherapeutic regimens, it is now consensual that the combination of immunotherapies tackling multiple cancer hallmarks can result in superior clinical outcomes. Here, we review in depth the pharmacological combination of DC-based vaccines that boost tumour elimination by eliciting and expanding effector immune cells, with the PD-1 inhibitor Nivolumab that allows blocking key tumour immune escape mechanisms. This combination represents an important step in cancer therapy, with a significant enhancement in patient survival in several types of tumours, paving an important way in establishing combinatorial immunotherapeutic strategies as first-line treatments.Elsevier2023-05-11T10:53:07Z2021-02-01T00:00:00Z2021-02info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10773/37674eng1043-661810.1016/j.phrs.2020.105309Calmeiro, JoãoCarrascal, Mylène A.Tavares, Adriana RamosFerreira, Daniel AlexandreGomes, CéliaCruz, Maria TeresaFalcão, AmílcarNeves, Bruno Miguelinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-02-22T12:13:33Zoai:ria.ua.pt:10773/37674Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:08:16.509690Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview
title Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview
spellingShingle Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview
Calmeiro, João
Antitumour immunotherapy
Immune checkpoint inhibitors
Nivolumab
Dendritic cell vaccines
Combinatory therapies
title_short Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview
title_full Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview
title_fullStr Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview
title_full_unstemmed Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview
title_sort Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: an overview
author Calmeiro, João
author_facet Calmeiro, João
Carrascal, Mylène A.
Tavares, Adriana Ramos
Ferreira, Daniel Alexandre
Gomes, Célia
Cruz, Maria Teresa
Falcão, Amílcar
Neves, Bruno Miguel
author_role author
author2 Carrascal, Mylène A.
Tavares, Adriana Ramos
Ferreira, Daniel Alexandre
Gomes, Célia
Cruz, Maria Teresa
Falcão, Amílcar
Neves, Bruno Miguel
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Calmeiro, João
Carrascal, Mylène A.
Tavares, Adriana Ramos
Ferreira, Daniel Alexandre
Gomes, Célia
Cruz, Maria Teresa
Falcão, Amílcar
Neves, Bruno Miguel
dc.subject.por.fl_str_mv Antitumour immunotherapy
Immune checkpoint inhibitors
Nivolumab
Dendritic cell vaccines
Combinatory therapies
topic Antitumour immunotherapy
Immune checkpoint inhibitors
Nivolumab
Dendritic cell vaccines
Combinatory therapies
description In the last decade, immunotherapy led to a paradigm shift in the treatment of numerous malignancies. Alongside with monoclonal antibodies blocking programmed cell death receptor-1 (PD-1)/PD-L1 and cytotoxic T- lymphocyte antigen 4 (CTLA-4) immune checkpoints, cell-based approaches such as CAR-T cells and dendritic cell (DC) vaccines have strongly contributed to pushing forward this thrilling field. While initial strategies were mainly focused on monotherapeutic regimens, it is now consensual that the combination of immunotherapies tackling multiple cancer hallmarks can result in superior clinical outcomes. Here, we review in depth the pharmacological combination of DC-based vaccines that boost tumour elimination by eliciting and expanding effector immune cells, with the PD-1 inhibitor Nivolumab that allows blocking key tumour immune escape mechanisms. This combination represents an important step in cancer therapy, with a significant enhancement in patient survival in several types of tumours, paving an important way in establishing combinatorial immunotherapeutic strategies as first-line treatments.
publishDate 2021
dc.date.none.fl_str_mv 2021-02-01T00:00:00Z
2021-02
2023-05-11T10:53:07Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10773/37674
url http://hdl.handle.net/10773/37674
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1043-6618
10.1016/j.phrs.2020.105309
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137735811792896